Management of Waldenstrom’s macroglobulinaemia
You must score at least 70% in this module to pass. Ensure you have read ‘Management of Waldenstrom’s macroglobulinaemia’ before attempting to complete the module.
This module can be taken up to three times. Once you have passed, you can view the correct answers and download a certificate as a record of your learning.
Additional CPD modules are available in the ‘My CPD’ section of your account.
Quiz Summary
0 of 15 Questions completed
Questions:
Information
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading…
You must sign in or sign up to start the quiz.
You must first complete the following:
Results
Results
0 of 15 Questions answered correctly
Your time:
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
Categories
- Not categorized 0%
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- Current
- Review
- Answered
- Correct
- Incorrect
- Question 1 of 15
1. Question
Which class of immunoglobulin is aberrantly secreted in Waldenstrom’s macroglobulinemia (WM)?
CorrectIncorrect - Question 2 of 15
2. Question
WM arises from the malignant transformation of which type of white blood cell?
CorrectIncorrect - Question 3 of 15
3. Question
Which clinical features are associated with CXCR4 mutations in WM?
CorrectIncorrect - Question 4 of 15
4. Question
WM-related peripheral neuropathy is reported in what percentage of WM patients as their presenting symptom?
CorrectIncorrect - Question 5 of 15
5. Question
Symptomatic hyperviscosity may be seen in WM, which of the following is a symptom of
this condition?CorrectIncorrect - Question 6 of 15
6. Question
Which of the following management strategies is indicated for patients with asymptomatic WM?
CorrectIncorrect - Question 7 of 15
7. Question
When is it considered safe to include rituximab when initiating treatment with rituximab-containing treatment regimens?
CorrectIncorrect - Question 8 of 15
8. Question
What frontline treatment for WM is preferred in those needing rapid disease control?
CorrectIncorrect - Question 9 of 15
9. Question
Which drug should be avoided in patients with WM-associated neuropathy?
CorrectIncorrect - Question 10 of 15
10. Question
What advice should be given to patients taking BTKis ahead of a planned major surgical procedure?
CorrectIncorrect - Question 11 of 15
11. Question
Which BTKi is approved by NICE as an option for treating WM in adults who have received at least one prior treatment?
CorrectIncorrect - Question 12 of 15
12. Question
Which of the following are considered to be toxicities of ibrutinib?
CorrectIncorrect - Question 13 of 15
13. Question
What class of drugs should be avoided following the development of resistance to ibrutinib or zanubrutinib?
CorrectIncorrect - Question 14 of 15
14. Question
What is a frequently recognised toxicity of zanubrutinib?
CorrectIncorrect - Question 15 of 15
15. Question
Which class of anti-coagulant should be avoided in patients undergoing treatment with ibrutinib?
CorrectIncorrect